Transcriptome Profiling of Hippocampal CA1 After Early-life Seizure-induced Preconditioning May Elucidate New Genetic Therapies for Epilepsy
Overview
Affiliations
Injury of the CA1 subregion induced by a single injection of kainic acid (1 × KA) in juvenile animals (P20) is attenuated in animals with two prior sustained neonatal seizures on P6 and P9. To identify gene candidates involved in the spatially protective effects produced by early-life conditioning seizures we profiled and compared the transcriptomes of CA1 subregions from control, 1 × KA- and 3 × KA-treated animals. More genes were regulated following 3 × KA (9.6%) than after 1 × KA (7.1%). Following 1 × KA, genes supporting oxidative stress, growth, development, inflammation and neurotransmission were upregulated (e.g. Cacng1, Nadsyn1, Kcng1, Aven, S100a4, GFAP, Vim, Hrsp12 and Grik1). After 3 × KA, protective genes were differentially over-expressed [e.g. Cat, Gpx7, Gad1, Hspa12A, Foxn1, adenosine A1 receptor, Ca(2+) adaptor and homeostasis proteins, Cacnb4, Atp2b2, anti-apoptotic Bcl-2 gene members, intracellular trafficking protein, Grasp and suppressor of cytokine signaling (Socs3)]. Distinct anti-inflammatory interleukins (ILs) not observed in adult tissues [e.g. IL-6 transducer, IL-23 and IL-33 or their receptors (IL-F2 )] were also over-expressed. Several transcripts were validated by real-time polymerase chain reaction (QPCR) and immunohistochemistry. QPCR showed that casp 6 was increased after 1 × KA but reduced after 3 × KA; the pro-inflammatory gene Cox1 was either upregulated or unchanged after 1 × KA but reduced by ~70% after 3 × KA. Enhanced GFAP immunostaining following 1 × KA was selectively attenuated in the CA1 subregion after 3 × KA. The observed differential transcriptional responses may contribute to early-life seizure-induced pre-conditioning and neuroprotection by reducing glutamate receptor-mediated Ca(2+) permeability of the hippocampus and redirecting inflammatory and apoptotic pathways. These changes could lead to new genetic therapies for epilepsy.
Yalcin A, Turunc E, Armagan G, Kanit L Turk J Pharm Sci. 2024; 21(4):259-266.
PMID: 39224027 PMC: 11589092. DOI: 10.4274/tjps.galenos.2023.47650.
Diaz-Villegas V, Pichardo-Macias L, Juarez-Mendez S, Ignacio-Mejia I, Cardenas-Rodriguez N, Antonio Vargas-Hernandez M Int J Mol Sci. 2024; 25(3).
PMID: 38338984 PMC: 10855401. DOI: 10.3390/ijms25031690.
Identification of potential crucial genes and therapeutic targets for epilepsy.
Wang S, Xie Z, Jun T, Ma X, Zhang M, Rao F Eur J Med Res. 2024; 29(1):43.
PMID: 38212777 PMC: 10782668. DOI: 10.1186/s40001-024-01643-8.
Maleki B, Modarres P, Salehi P, Vallian S Sci Rep. 2023; 13(1):21873.
PMID: 38072953 PMC: 10710998. DOI: 10.1038/s41598-023-49155-5.
Transcriptional Signatures of a Dynamic Epilepsy Process Reveal Potential Immune Regulation.
Huang Y, Wang Q, Liu X, Du W, Hao Z, Wang Y Mol Neurobiol. 2023; 61(6):3384-3396.
PMID: 37989981 PMC: 11087345. DOI: 10.1007/s12035-023-03786-x.